Clinical outcome in elderly patients older than 70 years with acute myocardial infarction after use of platelet glycoprotein IIb/IIIa receptor blocker during percutaneous coronary intervention : Comparison with those younger than 70 years.
- Author:
Doo Sun SIM
1
;
Myung Ho JEONG
;
Min Goo LEE
;
Young Joon HONG
;
Hyung Wook PARK
;
Weon KIM
;
Ju Han KIM
;
Young Keun AHN
;
Jeong Gwan CHO
;
Jong Chun PARK
;
Sang Wan RYU
;
Byoung Hee AHN
;
Sang Hyung KIM
;
Jung Chaee KANG
Author Information
1. The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea. myungho@chollian.net
- Publication Type:Original Article
- Keywords:
Platelets;
Receptor;
Acute Myocardial Infarction;
Angioplasty
- MeSH:
Aged*;
Angioplasty;
Blood Platelets*;
Death;
Follow-Up Studies;
Glycoproteins*;
Hemorrhage;
Humans;
Incidence;
Jeollanam-do;
Mortality;
Myocardial Infarction*;
Percutaneous Coronary Intervention*;
Retrospective Studies;
Risk Factors;
Stents;
Stroke
- From:Korean Journal of Medicine
2004;67(6):580-588
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: This study was designed to evaluate the safety and clinical benefits of a glycoprotein IIb/IIIa receptor inhibitor, ReoPro(R) in the elderly patients with acute myocardial infarction (AMI) (>or=70 years of age) undergoing percutaneous coronary intervention (PCI). METHODS: AMI patients who underwent PCI with use of ReoPro(R) at Chonnam National University Hospital from Jan 2000 to Jan 2002 were divided into two groups: Group I (>or=70 years of age: 74 +/- 2.4 years, n=28) and Group II (<70 years of age: 56 +/- 8.0 years, n=122). Early and long-term clinical outcomes after PCI were analyzed in a retrospective fashion. RESULTS: As for risk factors and angiographic profiles, there were no differences between the two groups. Stenting was performed in 18 patients (64%) in group I and in 78 patients (63%) in group II. The incidence of gastrointestinal bleeding was 3 patients in group I and no patient in group II (p=0.005). At one-month evaluation, three cardiac deaths developed in group I, but no cardiac death in group II (p=0.005). During a period of 25 +/- 10.4 months of clinical follow-up, three cardiac deaths (11%) occurred in group I and 3 (2%) in group II, four AMIs (3%) in group II, and one stroke (0.8%) in group II. Target lesion revascularization (TLR) was performed in two patients (7%) in group I and in 24 patients (19%) in group II. No differences were found in the incidences of these variables between the two groups. CONCLUSION: ReoPro(R) in elderly patients with AMI undergoing PCI entailed higher bleeding complications and early mortality. However, it has comparable clinical effect in elderly patients to younger patients during long-term clinical follow-up.
